Sara Gagno

List of Publications by Year
in descending order

28 papers	429 citations	11 h-index 840776	20 g-index 752698
28 all docs	28 docs citations	28 times ranked	736 citing authors

#	Article	IF	Citations
1	Clinical validity of a ‹scp›‹i›DPYD‹/i›‹/scp›â€based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. International Journal of Cancer, 2015, 137, 2971-2980.	5.1	70
2	Stressâ€induced anhedonia is associated with an increase in Alzheimer's diseaseâ€related markers. British Journal of Pharmacology, 2012, 165, 897-907.	5.4	54
3	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget, 2016, 7, 61970-61987.	1.8	41
4	SNCA 3â€²UTR genetic variants in patients with Parkinsonâ€™s disease and REM sleep behavior disorder. Neurological Sciences, 2017, 38, 1233-1240.	1.9	27
5	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PLoS ONE, 2020, 15, e0228822.	2.5	26
6	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Cells, 2019, 8, 584.	4.1	25
7	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. PLoS ONE, 2019, 14, e0225225.	2.5	21
8	Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations. Pharmaceutical Research, 2021, 38, 759-778.	3.5	19
9	A LCâ€"MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 187, 113358.	2.8	16
10	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122985.	2.3	16
11	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. International Journal of Molecular Sciences, 2016, 17, 1482.	4.1	12
12	Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). International Journal of Molecular Sciences, 2018, 19, 1510.	4.1	10
13	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). Cells, 2019, 8, 1186.	4.1	10
14	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Frontiers in Pharmacology, 2020, 11, 36.	3.5	10
15	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. Cancers, 2021, 13, 1705.	3.7	10
16	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. Clinical Breast Cancer, 2019, 19, 137-145.e4.	2.4	9
17	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. Oncotarget, 2017, 8, 22863-22875.	1.8	9
18	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. Frontiers in Pharmacology, 2018, 9, 1101.	3.5	8

#	Article	IF	Citations
19	A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112949.	2.8	7
20	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. PLoS ONE, 2021, 16, e0259137.	2.5	7
21	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. International Journal of Molecular Sciences, 2019, 20, 2082.	4.1	6
22	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiotherapy and Oncology, 2020, 149, 30-37.	0.6	6
23	A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 233-242.	1.4	5
24	Immunogenetics of prostate cancer: a still unexplored field of study. Pharmacogenomics, 2018, 19, 263-283.	1.3	3
25	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. Pharmacogenomics, 2020, 21, 995-1010.	1.3	2
26	Association of p53-autoantibodies with TP53 somatic mutational profile detected by next generation sequencing in advanced high-grade ovarian cancer. Annals of Oncology, 2017, 28, xi12.	1.2	0
27	Abstract P1-13-05: Role of pharmacogenetics in metastatic breast cancer (MBC) patients treated with exemestane as first-line hormonal therapy. An Italian multicentre study. , 2015, , .		0
28	Abstract 1420: IL17F-rs9463772 independently predicts long-term outcome in locally advanced rectal cancer. , 2016, , .		0